Allergy Therapeutics plc (AGYTF)
OTC PINK OTC PINK Primary 
Cavendish stays positive on Allergy Therapeutics as attention turns to key 2026 decision
Cavendish has reiterated its 13p target price on Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) after the company posted full-year results that were broadly in line with guidance and reflected a period of transition in its largest market. Revenue for the year to June 2025 came in at £55 million, effectively flat on last year but up about 2% at constant exchange rates.
Allergy Therapeutics steadies finances as it eyes Hong Kong listing
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has posted broadly steady annual results and outlined plans that point to a busier year ahead, including the possibility of a second stock market listing in Hong Kong. The biotechnology group, which develops treatments designed to reduce sensitivity to common allergens such as grass pollen and peanuts, reported revenue of £55 million for the year to 30 June, almost unchanged from the previous year's £55.2 million.
Allergy Therapeutics hits key safety milestone in peanut allergy study
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has cleared an important hurdle in the early testing of its experimental peanut allergy treatment, saying the highest planned dose in its PROTECT study has proved safe and well tolerated. The phase I/IIa trial has now completed dosing of the minimum required number of participants at that top dose, meeting its primary safety endpoint.
Allergy Therapeutics explores dual listing in Hong Kong
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) said it is evaluating a dual primary listing of its shares on the Main Board of the Hong Kong Stock Exchange as part of plans to expand its footprint in Asia. The biotechnology group, which is already listed on London's AIM market, said the move would aim to broaden its investor base and boost liquidity in its shares.
Allergy Therapeutics advances paediatric grass allergy trial into second year
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has started screening patients for the second year of its late-stage trial testing a long-acting grass pollen allergy treatment in children. The study, known as G308, is evaluating the company's Grass MATA MPL immunotherapy, a treatment designed to desensitise the immune system to grass pollen, a common cause of hay fever.
Allergy Therapeutics clears shareholder debt and secures new funding facility
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has wiped out its shareholder debt and strengthened its finances after investors exercised £55 million worth of warrants and agreed to a fresh £50 million loan facility running through to 2030. The AIM-listed biotechnology company, which develops allergy vaccines and treatments, said on Wednesday that its long-term backers SkyGem Acquisition and Southern Fox Investments had exercised 1.38 billion warrants issued under a 2023 funding agreement.
Allergy Therapeutics update delivers welcome dose of good news
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has given investors something to cheer about. The AIM-listed biotech climbed 3.3% to 8.25p after reporting encouraging progress in its early-stage trial for a peanut allergy vaccine.
Allergy Therapeutics advances peanut allergy vaccine with promising early trial data
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has reported further encouraging results from its ongoing phase I/IIa PROTECT trial, which is testing the safety and tolerability of its short-course peanut allergy vaccine, VLP Peanut. The company says the candidate was well tolerated in both healthy volunteers and peanut-allergic patients, with no serious safety concerns observed across any dose level.
Allergy Therapeutics publishes studies supporting new grass pollen allergy treatment
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF), the UK biotechnology company specialising in allergy immunotherapies, has published three new studies in the journal Allergy that strengthen the evidence for its investigational grass pollen allergy treatment, Grass MATA MPL. The papers focus on the treatment's use in combating allergic rhinoconjunctivitis, a condition involving both nasal and eye symptoms triggered by grass pollen.
Allergy Therapeutics says it is well-positioned for future growth
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) said it is gearing up for a busy year, as it reported stable revenue for the year to June 30. Updating on trading, it said it has submitted a marketing authorisation application for its Grass MATA MPL immunotherapy product and is preparing for a potential launch in the 2026 financial year.
Allergy Therapeutics presents promising allergy vaccine data
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF), a biotechnology firm specialising in allergy treatments, is showcasing key research findings at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Glasgow. Highlights include promising initial results from its peanut allergy vaccine candidate, which demonstrated safety and a significant reduction in allergic reactions in early human trials.
Grass MATA & peanut vaccine development to drive Allergy Therapeutics - ICYMI
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) chief executive Manuel Llobet and chief financial officer Shaun Furlong talked with Proactive about the company's financial turnaround and ongoing progress across key clinical programs. Allergy Therapeutics reported a return to operating profit before R&D, exceptional and fundraising costs, supported by topline growth and strict cost control.
